Site provided by Springer Healthcare. Part of the Springer Nature Group.
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
Nassif ME, Windsor SL, Borlaug BA, et al. Nat Med. 2021;27(11): 1954-1960.